Literature DB >> 35332431

Antibody to hepatitis B virus core antigen positivity is a predictor of non-alcoholic fatty liver disease severity.

Carlo Saitta1,2, Alessia Caruso3,4, Sergio Maimone3, Roberto Filomia3, Irene Cacciola3,4, Gaia Caccamo3, Maria Stella Franzè3,4, Concetta Pitrone3,4, Angela Alibrandi5, Michele Gaeta6, Giuseppe Mandraffino4,7, Giovanni Squadrito4,7, Giovanni Raimondo3,4.   

Abstract

Insufficient information is available about co-factors favoring the progression of non-alcoholic fatty liver disease (NAFLD) toward cirrhosis. We aimed to evaluate the impact of a limited alcohol intake and of occult hepatitis B virus (HBV) infection (OBI) on the severity of NAFLD. Three-hundred-seventy-four alcohol non-abusers and HBV surface antigen negative NAFLD patients (223 males; mean age 55.4 years), consecutively admitted to the outpatients clinic of a referral liver unit from January 1st, 2018 to December 31st, 2019, were studied. Anti-HBV core antigen antibody [(anti-HBc), a surrogate marker of OBI] was assessed in all patients. Patients were distinguished between teetotal and moderate alcohol consumers (intake of less than 30 g and 20 g if males or females, respectively). Liver fibrosis was non-invasively assessed by FIB-4 and transient elastography. Uni- and multivariate analyses were performed to identify predictors of advanced fibrosis. Patients had a mean BMI of 28.5 kg/m2, and the majority presented metabolic and cardio-vascular comorbidities [258 patients (69%) had insulin resistance/diabetes, 249 (66.6%) dyslipidemia, 200 (53.5%) arterial hypertension]. Multivariate analysis showed that anti-HBc positivity (p = 0.046, OR 2.153) was a factor associated with advanced fibrosis at FIB-4 score testing, whereas moderate alcohol intake was not associated with severe NAFLD both at FIB-4 and transient elastography evaluations. The study showed that a moderate alcohol intake has no impact on NAFLD severity and suggested that OBI might negatively affect the NAFLD outcome.
© 2022. The Author(s), under exclusive licence to Società Italiana di Medicina Interna (SIMI).

Entities:  

Keywords:  FIB-4 score; Non-alcoholic fatty liver disease; Occult HBV infection; Transient elastography

Mesh:

Substances:

Year:  2022        PMID: 35332431     DOI: 10.1007/s11739-022-02971-5

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   5.472


  30 in total

1.  Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation.

Authors:  David Goldberg; Ivo C Ditah; Kia Saeian; Mona Lalehzari; Andrew Aronsohn; Emmanuel C Gorospe; Michael Charlton
Journal:  Gastroenterology       Date:  2017-01-11       Impact factor: 22.682

2.  Modest alcohol consumption decreases the risk of non-alcoholic fatty liver disease: a meta-analysis of 43 175 individuals.

Authors:  Silvia Sookoian; Gustavo O Castaño; Carlos J Pirola
Journal:  Gut       Date:  2013-09-11       Impact factor: 23.059

Review 3.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.

Authors:  Naga Chalasani; Zobair Younossi; Joel E Lavine; Michael Charlton; Kenneth Cusi; Mary Rinella; Stephen A Harrison; Elizabeth M Brunt; Arun J Sanyal
Journal:  Hepatology       Date:  2017-09-29       Impact factor: 17.425

Review 4.  Is moderate alcohol use in nonalcoholic fatty liver disease good or bad? A critical review.

Authors:  Veeral H Ajmera; Norah A Terrault; Stephen A Harrison
Journal:  Hepatology       Date:  2017-04-28       Impact factor: 17.425

Review 5.  Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta-analysis.

Authors:  Guangqin Xiao; Sixian Zhu; Xiao Xiao; Lunan Yan; Jiayin Yang; Gang Wu
Journal:  Hepatology       Date:  2017-09-26       Impact factor: 17.425

Review 6.  Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.

Authors:  Zobair Younossi; Quentin M Anstee; Milena Marietti; Timothy Hardy; Linda Henry; Mohammed Eslam; Jacob George; Elisabetta Bugianesi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-09-20       Impact factor: 46.802

7.  Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD).

Authors:  Winston Dunn; Arun J Sanyal; Elizabeth M Brunt; Aynur Unalp-Arida; Michael Donohue; Arthur J McCullough; Jeffrey B Schwimmer
Journal:  J Hepatol       Date:  2012-04-17       Impact factor: 25.083

8.  Among Patients With Nonalcoholic Fatty Liver Disease, Modest Alcohol Use Is Associated With Less Improvement in Histologic Steatosis and Steatohepatitis.

Authors:  Veeral Ajmera; Patricia Belt; Laura A Wilson; Ryan M Gill; Rohit Loomba; David E Kleiner; Brent A Neuschwander-Tetri; Norah Terrault
Journal:  Clin Gastroenterol Hepatol       Date:  2018-03-14       Impact factor: 11.382

9.  Synergistic association between alcohol intake and body mass index with serum alanine and aspartate aminotransferase levels in older adults: the Rancho Bernardo Study.

Authors:  R Loomba; R Bettencourt; E Barrett-Connor
Journal:  Aliment Pharmacol Ther       Date:  2009-09-08       Impact factor: 8.171

Review 10.  Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.

Authors:  Zobair M Younossi; Aaron B Koenig; Dinan Abdelatif; Yousef Fazel; Linda Henry; Mark Wymer
Journal:  Hepatology       Date:  2016-02-22       Impact factor: 17.425

View more
  1 in total

Review 1.  Occult Hepatitis B Virus Infection: An Update.

Authors:  Carlo Saitta; Teresa Pollicino; Giovanni Raimondo
Journal:  Viruses       Date:  2022-07-08       Impact factor: 5.818

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.